Dr Natalie Hale Wallace, MD, MPH | |
2925 Debarr Rd Ste 300, Anchorage, AK 99508-2974 | |
(907) 279-3155 | |
(907) 279-3154 |
Full Name | Dr Natalie Hale Wallace |
---|---|
Gender | Female |
Speciality | Hematology/oncology |
Experience | 10 Years |
Location | 2925 Debarr Rd Ste 300, Anchorage, Alaska |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1386059061 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207RH0003X | Internal Medicine - Hematology & Oncology | 159302 (Alaska) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Providence Alaska Medical Center | Anchorage, AK | Hospital |
Alaska Regional Hospital | Anchorage, AK | Hospital |
Mat-su Regional Medical Center | Palmer, AK | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Alaska Oncology And Hematology Llc | 0648265090 | 8 |
News Archive
Researchers from St. Jude Children's Research Hospital and the Pediatric Brain Tumor Consortium (PBTC) presented at the American Society of Clinical Oncology the findings of a pediatric brain tumor study using an experimental drug that targets the underlying genetic makeup of the tumor. The research focused on a new way to attack the tumors by blocking the Hedgehog pathway that is linked to approximately 20 percent of medulloblastomas.
Time taken to detect brain tumours could soon be significantly reduced thanks to an ongoing pioneering project led by the University of Liverpool with the Nuclear Physics Group and Technology departments at the Science and Technology Facilities Council (STFC) at Daresbury Laboratory.
Galectin Therapeutics Inc., the leader in developing carbohydrate-based therapeutic compounds to inhibit galectin receptors, today announced the formation of its Liver Fibrosis Clinical Trials Advisory Board comprised of key opinion leaders from Emory Hospital and School of Medicine, Massachusetts General Hospital and Harvard School of Medicine, University of Michigan Hospital and School of Medicine, Mount Sinai Hospital and School of Medicine, and University of Wisconsin Hospital and School of Medicine.
Death from a heart attack or stroke may be the first cardiovascular disease (CVD) event in some people who smoke cigarettes and CVD is the leading adverse health effect among smokers, according to new research published today in the Journal of the American Heart Association, an open access journal of the American Heart Association.
› Verified 2 days ago
Entity Name | Alaska Oncology And Hematology Llc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1487713848 PECOS PAC ID: 0648265090 Enrollment ID: O20040416000215 |
News Archive
Researchers from St. Jude Children's Research Hospital and the Pediatric Brain Tumor Consortium (PBTC) presented at the American Society of Clinical Oncology the findings of a pediatric brain tumor study using an experimental drug that targets the underlying genetic makeup of the tumor. The research focused on a new way to attack the tumors by blocking the Hedgehog pathway that is linked to approximately 20 percent of medulloblastomas.
Time taken to detect brain tumours could soon be significantly reduced thanks to an ongoing pioneering project led by the University of Liverpool with the Nuclear Physics Group and Technology departments at the Science and Technology Facilities Council (STFC) at Daresbury Laboratory.
Galectin Therapeutics Inc., the leader in developing carbohydrate-based therapeutic compounds to inhibit galectin receptors, today announced the formation of its Liver Fibrosis Clinical Trials Advisory Board comprised of key opinion leaders from Emory Hospital and School of Medicine, Massachusetts General Hospital and Harvard School of Medicine, University of Michigan Hospital and School of Medicine, Mount Sinai Hospital and School of Medicine, and University of Wisconsin Hospital and School of Medicine.
Death from a heart attack or stroke may be the first cardiovascular disease (CVD) event in some people who smoke cigarettes and CVD is the leading adverse health effect among smokers, according to new research published today in the Journal of the American Heart Association, an open access journal of the American Heart Association.
› Verified 2 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Natalie Hale Wallace, MD, MPH 2925 Debarr Rd Ste 300, Anchorage, AK 99508-2974 Ph: (907) 279-3155 | Dr Natalie Hale Wallace, MD, MPH 2925 Debarr Rd Ste 300, Anchorage, AK 99508-2974 Ph: (907) 279-3155 |
News Archive
Researchers from St. Jude Children's Research Hospital and the Pediatric Brain Tumor Consortium (PBTC) presented at the American Society of Clinical Oncology the findings of a pediatric brain tumor study using an experimental drug that targets the underlying genetic makeup of the tumor. The research focused on a new way to attack the tumors by blocking the Hedgehog pathway that is linked to approximately 20 percent of medulloblastomas.
Time taken to detect brain tumours could soon be significantly reduced thanks to an ongoing pioneering project led by the University of Liverpool with the Nuclear Physics Group and Technology departments at the Science and Technology Facilities Council (STFC) at Daresbury Laboratory.
Galectin Therapeutics Inc., the leader in developing carbohydrate-based therapeutic compounds to inhibit galectin receptors, today announced the formation of its Liver Fibrosis Clinical Trials Advisory Board comprised of key opinion leaders from Emory Hospital and School of Medicine, Massachusetts General Hospital and Harvard School of Medicine, University of Michigan Hospital and School of Medicine, Mount Sinai Hospital and School of Medicine, and University of Wisconsin Hospital and School of Medicine.
Death from a heart attack or stroke may be the first cardiovascular disease (CVD) event in some people who smoke cigarettes and CVD is the leading adverse health effect among smokers, according to new research published today in the Journal of the American Heart Association, an open access journal of the American Heart Association.
› Verified 2 days ago
Andrea Caballero, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 3220 Providence Dr Ste E3-080, Anchorage, AK 99508 Phone: 907-375-8785 Fax: 907-375-8788 | |
Daryl M. Mcclendon, M.D., P.C. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 3851 Piper Street, Suite U466, Anchorage, AK 99508 Phone: 907-569-1333 Fax: 907-569-1433 | |
Dr. Loretta Leih-sheng Lee, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 4001 Dale St, Suite 210, Anchorage, AK 99508 Phone: 907-929-5880 Fax: 907-929-5882 | |
Dr. Richard Merle Farleigh, M.D. Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 4120 Laurel St, Suite 202, Anchorage, AK 99508 Phone: 907-561-4293 | |
Alexis Leandro Delgado, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 4300 B St, Suite 200, Anchorage, AK 99503 Phone: 907-375-3355 Fax: 907-375-3351 | |
Geronimo Sahagun, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 2841 Debarr Road, Suite 50, Anchorage, AK 99508 Phone: 907-276-2811 Fax: 907-276-2810 | |
Dr. Tram Phuong Chu, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 3200 Providence Dr, Suite B111, Anchorage, AK 99508 Phone: 907-212-7890 Fax: 907-212-2374 |